News
Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...
16h
Verywell Health on MSNWegovy vs. Ozempic: Which Is the Better Weight Loss Drug?Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.
Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.
Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...
Weight loss drugs are getting more popular, even for teenagers and pre-teens -- but while many doctors have reported ...
3d
News-Medical.Net on MSNSemaglutide clears liver inflammation and cuts fibrosis in MASH patients, trial showsA phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...
Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...
Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...
The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...
7h
Stocktwits on MSNRetail Traders Flock To ZyVersa As IC 100 Obesity Plan Looks To Fill GLP-1 GapsShares of ZyVersa Therapeutics surged Wednesday, drawing heavy attention from retail investors after the company unveiled new ...
21h
Pharmaceutical Technology on MSNNovo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demandShares in Novo Nordisk were still up after Q1 2025 witnessed a total revenue jump by 18%, compared to Q1 2024.
Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results